California-based Agendia's MammaPrint 70-gene breast cancer recurrence test is set for reimbursement in Germany following a positive opinion for coverage by the country's Federal Joint Committee, or GB-A.
The next-generation sequencing test screens for the most common genes associated with breast cancer recurrence and provides a score signifying the likely outcome. Agendia recently launched MammaPrint and also its BluePrint molecular subtyping test in Germany through a partnership with two German companies -- PathoNext, of Leipzig, and HiSS Diagnostics in Breisgau. Samples may be sent to PathoNext's lab or to Agendia's central lab.
